Synthesis and SAR study of modulators inhibiting tRXRα-dependent AKT activation

European Journal of Medicinal Chemistry

Volumn 62, Issue , 2013, Pages 632-648

  Wang, Zhi Gang ^a   Chen, Liqun ^a,b   Chen, Jiebo ^b   Zheng, Jian Feng ^a   Gao, Weiwei ^a   Zeng, Zhiping ^a   Zhou, Hu ^a,b   Zhang, Xiao Kun ^a,b   Huang, Pei Qiang ^a   Su, Ying ^a,b  

^a XIAMEN UNIVERSITY   (China)

^b BURNHAM INSTITUTE   (United States)

Author keywords

AKT activation; RXR ; Sulindac analogs; tRXR modulator

Indexed keywords

PROTEIN KINASE B INHIBITOR;

ARTICLE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; DRUG SYNTHESIS; ENZYME ACTIVATION; STRUCTURE ACTIVITY RELATION;

DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; RETINOID X RECEPTOR ALPHA; STRUCTURE-ACTIVITY RELATIONSHIP; SULINDAC;

EID: 84874141901     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2013.01.012     Document Type: Article

References (30)

1. P. Germain, P. Chambon, G. Eichele, R.M. Evans, M.A. Lazar, M. Leid, A.R. De Lera, R. Lotan, D.J. Mangelsdorf, and H. Gronemeyer International Union of Pharmacology. LXIII. Retinoid X receptors Pharmacological Reviews 58 2006 760 772
2. A. Szanto, V. Narkar, Q. Shen, I.P. Uray, P.J.A. Davies, and L. Nagy Retinoid X receptors: X-ploring their (patho)physiological functions Cell Death & Differentiation 11 2004 S126 S143
3. P. Lefebvre, Y. Benomar, and B. Staels Retinoid X receptors: common heterodimerization partners with distinct functions Trends in Endocrinology & Metabolism 21 2010 676 683
4. E. Pérez, W. Bourguet, H. Gronemeyer, and A.R. de Lera Modulation of RXR function through ligand design Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids 1821 2012 57 69
5. M.I. Dawson, and Z. Xia The retinoid X receptors and their ligands Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids 1821 2012 21 56
6. K. Wu, H.T. Kim, J.L. Rodriquez, S.G. Hilsenbeck, S.K. Mohsin, X.C. Xu, W.W. Lamph, J.G. Kuhn, J.E. Green, and P.H. Brown Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069 Cancer Epidemiology, Biomarkers & Prevention 11 2002 467 474
7. N. Bushue, and Y.-J.Y. Wan Retinoid pathway and cancer therapeutics Advanced Drug Delivery Reviews 62 2010 1285 1298
8. R. Talpur, S. Ward, N. Apisarnthanarax, J. Breuer-McHam, and M. Duvic Optimizing bexarotene therapy for cutaneous T-cell lymphoma Journal of the American Academy of Dermatology 47 2002 672 684
9. M.I. Dawson, and X.-K. Zhang Discovery and design of retinoic acid receptor and retinoid X receptor class- and subtype-selective synthetic analogs of all-trans-retinoic acid and 9-cis-retinoic acid Current Medicinal Chemistry 9 2002 623 637
10. F.J. Esteva, J. Glaspy, S. Baidas, L. Laufman, L. Hutchins, M. Dickler, D. Tripathy, R. Cohen, A. DeMichele, R.C. Yocum, C.K. Osborne, D.F. Hayes, G.N. Hortobagyi, E. Winer, and G.D. Demetri Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 21 2003 999 1006
11. W.C. Yen, and W.W. Lamph A selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced prostate cancer The Prostate 66 2006 305 316
12. R. Ramlau, P. Zatloukal, J. Jassem, P. Schwarzenberger, S.V. Orlov, M. Gottfried, J.R. Pereira, G. Temperley, R. Negro-Vilar, S. Rahal, J.K. Zhang, A. Negro-Vilar, and Z.E. Dziewanowska Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I Journal of Clinical Oncology 26 2008 1886 1892
13. C. Haanen Sulindac and its derivatives: a novel class of anticancer agents Current Opinion in Investigational Drugs 2 2001 677 683
14. Y. Yamamoto, M.J. Yin, K.M. Lin, and R.B. Gaynor Sulindac inhibits activation of the NF-kappaB pathway The Journal of Biological Chemistry 274 1999 27307 27314
15. L. Zhang, J. Yu, B.H. Park, K.W. Kinzler, and B. Vogelstein Role of BAX in the apoptotic response to anticancer agents Science 290 2000 989 992
16. N.M. Davies, and M.S. Watson Clinical pharmacokinetics of sulindac. A dynamic old drug Clinical Pharmacokinetics 32 1997 437 459
17. S. Grosch, T.J. Maier, S. Schiffmann, and G. Geisslinger Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors Journal of the National Cancer Institute 98 2006 736 747
18. H. Zhou, W. Liu, Y. Su, Z. Wei, J. Liu, S.K. Kolluri, H. Wu, Y. Cao, J. Chen, Y. Wu, T. Yan, X. Cao, W. Gao, A. Molotkov, F. Jiang, W.G. Li, B. Lin, H.P. Zhang, J. Yu, S.P. Luo, J.Z. Zeng, G. Duester, P.Q. Huang, and X.K. Zhang NSAID sulindac and its analog bind RXRalpha and inhibit RXRalpha-dependent AKT signaling Cancer Cell 17 2010 560 573
19. G.H. Wang, F.Q. Jiang, Y.H. Duan, Z.P. Zeng, F. Chen, Y. Dai, J.B. Chen, J.X. Liu, J. Liu, H. Zhou, H.F. Chen, J.Z. Zeng, Y. Su, X.S. Yao, and X.K. Zhang Targeting truncated retinoid X receptor-alpha by CF31 induces TNF-alpha-dependent apoptosis Cancer Research 73 2013 307 318
20. Y. Sato, N. Ramalanjaona, T. Huet, N. Potier, J. Osz, P. Antony, C. Peluso-Iltis, P. Poussin-Courmontagne, E. Ennifar, Y. Mely, A. Dejaegere, D. Moras, and N. Rochel The "Phantom Effect" of the rexinoid LG100754: structural and functional insights PloS One 5 2010 e15119
21. R.A. Friesner, J.L. Banks, R.B. Murphy, T.A. Halgren, J.J. Klicic, D.T. Mainz, M.P. Repasky, E.H. Knoll, M. Shelley, J.K. Perry, D.E. Shaw, P. Francis, and P.S. Shenkin Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy Journal of Medicinal Chemistry 47 2004 1739 1749
22. H. Zhang, R. Zhou, L. Li, J. Chen, L. Chen, C. Li, H. Ding, L. Yu, L. Hu, H. Jiang, and X. Shen Danthron functions as a retinoic X receptor antagonist by stabilizing tetramers of the receptor The Journal of Biological Chemistry 286 2011 1868 1875
23. H. Zhang, L. Chen, J. Chen, H. Jiang, and X. Shen Structural basis for retinoic X receptor repression on the tetramer The Journal of Biological Chemistry 286 2011 24593 24598
24. G.A. Piazza, A.L. Rahm, M. Krutzsch, G. Sperl, N.S. Paranka, P.H. Gross, K. Brendel, R.W. Burt, D.S. Alberts, and R. Pamukcu Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis Cancer Research 55 1995 3110 3116
25. R.K. Verma, R. Singla, and V.T. Punniyakoti A facile synthesis of 2-benzyloxy/2-(4-isopropylbenzyloxy)-2-methyl-3-(4-substituted phenyl)propanoic acid based insulin snesitizing agents: RSR13-15 and PKR13-15 Medicinal Chemistry Research 13 2004 660 676
26. R. Sieckmann, DE: 3720791, Patent (1989-01-05).
27. S. Hagishita, M. Yamada, K. Shirahase, T. Okada, Y. Murakami, Y. Ito, T. Matsuura, M. Wada, T. Kato, M. Ueno, Y. Chikazawa, K. Yamada, T. Ono, I. Teshirogi, and M. Ohtani Potent inhibitors of secretory phospholipase A2: synthesis and inhibitory activities of indolizine and indene derivatives Journal of Medicinal Chemistry 39 1996 3636 3658
28. S. Gerhard, G. Paul, B. Klaus, G.A. Piazza, P. Rifat, WO9747295, Patent (1997-12-18).
29. J. Lu, M.I. Dawson, Q.Y. Hu, Z. Xia, J.D. Dambacher, M. Ye, X.-K. Zhang, and E. Li The effect of antagonists on the conformational exchange of the retinoid X receptor alpha ligand-binding domain Magnetic Resonance in Chemistry 47 2009 1071 1080
30. N. Lu, J. Liu, J. Liu, C. Zhang, F. Jiang, H. Wu, L. Chen, W. Zeng, X. Cao, T. Yan, G. Wang, H. Zhou, B. Lin, X. Yan, X.K. Zhang, and J.Z. Zeng Antagonist effect of triptolide on AKT activation by truncated retinoid X receptor-alpha PloS One 7 2012 e35722